Trial · NCT05014672
Results by group59
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 59 of 59
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1600 mg/Day | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥70% ALP Reduction from Baseline | 0 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Placebo | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥70% ALP Reduction from Baseline | 0 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1200 mg/Day | ALP <1.50×ULN and Total Bilirubin ≤1×ULN and ≥40% ALP Reduction from Baseline | 0 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1600 mg/Day | ALP <1.50×ULN and Total Bilirubin ≤1×ULN and ≥40% ALP Reduction from Baseline | 2 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Placebo | ALP <1.50×ULN and Total Bilirubin ≤1×ULN and ≥40% ALP Reduction from Baseline | 0 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1200 mg/Day | ALP <1.00×ULN and Total Bilirubin ≤1×ULN | 0 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1600 mg/Day | ALP <1.00×ULN and Total Bilirubin ≤1×ULN | 1 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Placebo | ALP <1.00×ULN and Total Bilirubin ≤1×ULN | 0 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1200 mg/Day | Total bilirubin <0.6×ULN | 19 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1600 mg/Day | Total bilirubin <0.6×ULN | 18 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Placebo | Total bilirubin <0.6×ULN | 19 | participants | |
| Change in ALP at Week 24 Compared to Baseline, Where Setanaxib Doses Are Combined | Setanaxib Doses Combined | 0.87 | 95% Confidence Interval 0.804 to 0.931 | ratio | |
| Change in ALP at Week 24 Compared to Baseline, Where Setanaxib Doses Are Combined | Placebo | 1.03 | 95% Confidence Interval 0.930 to 1.135 | ratio | |
| Change in Fatigue at Week 24 Compared to Baseline, as Assessed by the PROMIS Short Form-Fatigue 7b Daily, Where Setanaxib Doses Are Combined | Setanaxib Doses Combined | -2.12 | 95% Confidence Interval -4.925 to 0.678 | T-scores | |
| Change in Fatigue at Week 24 Compared to Baseline, as Assessed by the PROMIS Short Form-Fatigue 7b Daily, Where Setanaxib Doses Are Combined | Placebo | -1.45 | 95% Confidence Interval -5.372 to 2.467 | T-scores | |
| Change in Fatigue at Week 24 Compared to Baseline, as Assessed by the PBC-40 Questionnaire (PBC 40) Fatigue Domain, Where Setanaxib Doses Are Combined | Setanaxib Doses Combined | -1.64 | 95% Confidence Interval -4.096 to 0.826 | units on a scale | |
| Change in Fatigue at Week 24 Compared to Baseline, as Assessed by the PBC-40 Questionnaire (PBC 40) Fatigue Domain, Where Setanaxib Doses Are Combined | Placebo | -1.84 | 95% Confidence Interval -5.176 to 1.492 | units on a scale | |
| Change in Liver Stiffness at Week 24 Compared to Screening, Where Setanaxib Doses Are Combined | Setanaxib Doses Combined | 0.83 | 95% Confidence Interval 0.750 to 0.921 | ratio | |
| Change in Liver Stiffness at Week 24 Compared to Screening, Where Setanaxib Doses Are Combined | Placebo | 0.92 | 95% Confidence Interval 0.809 to 1.056 | ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05014672/results?page=3